Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 3.02B P/E - EPS this Y 525.00% Ern Qtrly Grth 888.60%
Income -6.09M Forward P/E 352.35 EPS next Y 88.20% 50D Avg Chg 16.00%
Sales 366.38M PEG 2.03 EPS past 5Y - 200D Avg Chg 3.00%
Dividend N/A Price/Book 5.03 EPS next 5Y 66.00% 52W High Chg -25.00%
Recommedations 2.80 Quick Ratio 8.78 Shares Outstanding 51M 52W Low Chg 26.00%
Insider Own 1.07% ROA -0.43% Shares Float 50.43M Beta 0.57
Inst Own 102.09% ROE -1.01% Shares Shorted/Prior 2.94M/2.65M Price 59.90
Gross Margin 74.94% Profit Margin -1.66% Avg. Volume 668,198 Target Price 71.73
Oper. Margin 3.93% Earnings Date Apr 29 Volume 815,891 Change -3.00%
About Axonics, Inc.

Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.

Axonics, Inc. News
03/22/24 Axonics Stockholders Approve Merger Agreement with Boston Scientific
03/21/24 Axonics Provides Update on Inter Partes Review Proceedings
03/14/24 Axonics Receives CE Mark Approval for Fourth-Generation Rechargeable Sacral Neuromodulation System
03/01/24 Axonics Full Year 2023 Earnings: EPS Beats Expectations
02/29/24 Axonics Responds to ITC Action by Medtronic
07:01 PM Axonics Inc (AXNX) Reports Robust Revenue Growth and Margin Expansion in Q4 and FY 2023
05:40 PM Axonics Modulation Technologies (AXNX) Q4 Earnings and Revenues Surpass Estimates
04:01 PM Axonics Reports Fourth Quarter and Fiscal Year 2023 Financial Results
02/02/24 Insider Sell: Chief Medical Officer Karen Noblett Sells 11,288 Shares of Axonics Inc (AXNX)
01/31/24 Boston Scientific Announces Results for Fourth Quarter and Full Year 2023
01/17/24 Are Medical Stocks Lagging Elevance Health, Inc. (ELV) This Year?
01/08/24 Why Axonics Stock Soared Today
01/08/24 Boston Scientific to Acquire Axonics For About $3.7 Billion
01/08/24 Axonics Announces Definitive Agreement to be Acquired by Boston Scientific
01/08/24 Boston Scientific Announces Agreement to Acquire Axonics, Inc.
01/08/24 Axonics Reports Preliminary 4Q23 and Fiscal Year 2023 Revenue
12/27/23 Axonics to Present at the J.P. Morgan Healthcare Conference
12/04/23 When Will Axonics, Inc. (NASDAQ:AXNX) Become Profitable?
11/20/23 Wall Street Analysts Believe Axonics (AXNX) Could Rally 25.1%: Here's is How to Trade
11/07/23 Axonics (NASDAQ:AXNX) delivers shareholders solid 29% CAGR over 5 years, surging 8.0% in the last week alone
AXNX Chatroom

User Image DonCorleone77 Posted - 5 days ago

$AXNX $BSX Axonics shareholders approve merger with Boston Scientific Axonics (AXNX) announced that its stockholders have voted to adopt Axonics' merger agreement with Boston Scientific (BSX). The closing of the transaction is expected to occur in the first half of 2024 and remains subject to certain conditions, including receipt of approvals or clearances, or the expiration, termination or waiver of applicable waiting periods under U.S. and foreign antitrust laws.

User Image Stock_Titan Posted - 5 days ago

$AXNX $BSX Axonics Stockholders Approve Merger Agreement with Boston Scientific https://www.stocktitan.net/news/AXNX/axonics-stockholders-approve-merger-agreement-with-boston-ps1hiyxbm0bb.html

User Image Mergerbrief Posted - 6 days ago

$AXNX $BSX - $AXNX Shareholder Vote mergerbrief.com

User Image Stock_Titan Posted - 6 days ago

$AXNX Axonics Provides Update on Inter Partes Review Proceedings https://www.stocktitan.net/news/AXNX/axonics-provides-update-on-inter-partes-review-mvpijlvcgi07.html

User Image Stock_Titan Posted - 2 weeks ago

$AXNX Axonics Receives CE Mark Approval for Fourth-Generation Rechargeable Sacral Neuromodulation System https://www.stocktitan.net/news/AXNX/axonics-receives-ce-mark-approval-for-fourth-generation-rechargeable-thi1qkibwrkl.html

User Image MergerObserver Posted - 2 weeks ago

$AXNX $BSX Axonics and Boston Scientific pulled and refiled HSR on March 4 for their proposed merger. The applicable 30-day waiting period is scheduled to expire on April 3.

User Image Stock_Titan Posted - 02/29/24

$AXNX Axonics Responds to ITC Action by Medtronic https://www.stocktitan.net/news/AXNX/axonics-responds-to-itc-action-by-0svmy1ir8tgv.html

User Image Mergerbrief Posted - 02/29/24

$AXNX $BSX - HSR Possible expires Mergerbrief.com

User Image epsguid Posted - 4 weeks ago

$AXNX reported earnings of $0.13, consensus was $0.06 via @eWhispers #epsbeat http://eps.sh/d/axnx

User Image Stock_Titan Posted - 4 weeks ago

$AXNX Axonics Reports Fourth Quarter and Fiscal Year 2023 Financial Results https://www.stocktitan.net/news/AXNX/axonics-reports-fourth-quarter-and-fiscal-year-2023-financial-tqemdp0if3d7.html

User Image MergerObserver Posted - 1 month ago

$AXNX $BSX Axonics filed a definitive proxy statement for its proposed $3.7 billion acquisition by Boston Scientific. Target shareholders are scheduled to vote at 9am PT on March 22. Regulatory conditions: HSR was filed on January 30, and the applicable 30-day waiting period is set to expire on February 29. The parties will also file merger notifications with other governmental authorities in connection with the merger. Closing guidance: First half of 2024

User Image TickerDD_com Posted - 1 month ago

From 2/16/2024, looking back across 22 Month-Ends for AXNX, Percentage Change of Average Monthly Price had Equal (50%) while Percentage Change of Average Monthly Volume had More Positives (95%) $AXNX #AXNX #AXNXStock #TickerDD #AXNXPrice https://www.youtube.com/watch?v=DzfjVlA6g1Y

User Image InvestWhatUCanLose Posted - 1 month ago

$ICU anyone how want a case study of a successful medical device company that made it to a BO at 71$ per share refer $AXNX (IPO was at 15$ in 2018) which has OSS similar to ICU. We are the next AXNX imo. In next 2-3 years we will be same as AXNX or even better ..

User Image insiderbuyingselling Posted - 1 month ago

$AXNX new insider selling: 11288 shares. http://insiderbuyingselling.com/?t=AXNX

User Image VirmoMopire Posted - 01/30/24

$AXNX Looks like it is making some moves today! 📈

User Image ChartMill Posted - 2 months ago

Bull flags detected by our stock screener in $DNN, $NVO, $LLY, $ELF and $AXNX. https://www.chartmill.com/stock/stock-screener?sid=13&f=v1_50b500,s_bf,exch_us&v=3&timeframe=DAILY&type=CANDLES&o1=3&op1=200,16711680&cl=F&months=0&o2=3&op2=50,255&width=400&o3=62&utm_source=Bull_Flags&utm_medium=stocktwits&utm_campaign=screen

User Image tickeron Posted - 2 months ago

If you’re trading this week, Read This! $AXNX Stochastic Oscillator left the overbought zone. View odds of downtrend. https://srnk.us/go/4976995

User Image risenhoover Posted - 2 months ago

$AXNX AXNX / Axonics, Inc. downgraded by Needham https://fintel.io/sfo/us/axnx?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=upgrade

User Image Thestocktraderhubzee Posted - 2 months ago

WATCHLIST JAN 17 2024 $ARMK Goldman Sachs Initiates Coverage On Aramark with Buy Rating, Announces Price Target of $33 $NVEI Wells Fargo Initiates Coverage On Nuvei with Equal-Weight Rating, Announces Price Target of $29 $TEAM Mizuho Maintains Buy on Atlassian, Raises Price Target to $265 $SUI Truist Securities Downgrades Sun Communities to Hold, Raises Price Target to $143 $AXNX Truist Securities Downgrades Axonics to Hold, Lowers Price Target to $71

User Image risenhoover Posted - 2 months ago

$AXNX AXNX / Axonics, Inc. downgraded by Truist Securities https://fintel.io/sfo/us/axnx?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=upgrade

User Image tickeron Posted - 2 months ago

A.I.dvisor made a bullish call on $AXNX, netting in a 22.39% gain over 5 days https://srnk.us/go/4970388

User Image tickeron Posted - 2 months ago

A.I.dvisor made a bullish call on $AXNX, netting in a 19.94% gain over 1 month https://srnk.us/go/4970366

User Image STCKPRO Posted - 2 months ago

$AXNX NEW ARTICLE : Analysts’ Opinions Are Mixed on These Healthcare Stocks: Axonics Modulation Technologies (AXNX) and Siemens Healthineers AG (OtherSEMHF) https://www.stck.pro/news/AXNX/72839199/

User Image Thestocktraderhubzee Posted - 2 months ago

WATCHLIST JAN 16 2024 $AXNX Truist Securities Downgrades Axonics to Hold, Lowers Price Target to $71 $VERX Citigroup Maintains Neutral on Vertex, Lowers Price Target to $27 $SWN Citigroup Maintains Buy on Southwestern Energy, Raises Price Target to $8.24 $MRVL Citigroup Maintains Buy on Marvell Tech, Raises Price Target to $75 $ICE Citigroup Maintains Buy on Intercontinental Exchange, Raises Price Target to $146

User Image tickeron Posted - 2 months ago

A.I.dvisor made a bullish call on $AXNX, netting in a 31.96% gain over 1 month https://srnk.us/go/4969428

User Image risenhoover Posted - 2 months ago

$AXNX AXNX / Axonics, Inc. downgraded by Truist Securities https://fintel.io/sfo/us/axnx?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=upgrade

User Image tickeron Posted - 2 months ago

This is why Hedge Funds use A.I. $AXNX The volume increased for four consecutive days, resulting in a record-breaking daily growth of 313% of the 65-Day Volume Moving Average. View odds of downtrend. https://srnk.us/go/4967960

User Image StockInvest_us Posted - 2 months ago

Signal alert: $AXNX - Overvalued https://stockinvest.us/l/FUnBq6dex3

User Image risenhoover Posted - 2 months ago

$AXNX AXNX / Axonics, Inc. downgraded by Piper Sandler https://fintel.io/sfo/us/axnx?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=upgrade

User Image risenhoover Posted - 2 months ago

$AXNX AXNX / Axonics, Inc. downgraded by CL King https://fintel.io/sfo/us/axnx?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=upgrade

Analyst Ratings
RBC Capital Sector Perform Feb 29, 24
Needham Hold Jan 17, 24
Truist Securities Hold Jan 16, 24
Truist Securities Hold Jan 12, 24
CL King Neutral Jan 12, 24
Piper Sandler Neutral Jan 12, 24
Leerink Partners Market Perform Jan 12, 24
Wells Fargo Equal-Weight Jan 10, 24
Wolfe Research Peer Perform Jan 9, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Sama Rinda Chief Operating Offi.. Chief Operating Officer Jan 31 Option 0.00 28,000 83,854 02/02/24
Noblett Karen Chief Medical Office.. Chief Medical Officer Jan 31 Sell 67.74 11,288 764,649 34,428 02/02/24
Noblett Karen Chief Medical Office.. Chief Medical Officer Jan 31 Option 0 27,500 45,716 02/02/24
Woock John EVP, Chief Mktg/Strt.. EVP, Chief Mktg/Strtgy Officer Jan 31 Sell 67.74 15,899 1,076,998 77,403 02/02/24
Woock John EVP, Chief Mktg/Strt.. EVP, Chief Mktg/Strtgy Officer Jan 31 Option 0 28,000 93,302 02/02/24
Ford Alfred J Jr Chief Commercial Off.. Chief Commercial Officer Jan 31 Sell 67.74 16,615 1,125,500 43,450 02/02/24
Ford Alfred J Jr Chief Commercial Off.. Chief Commercial Officer Jan 31 Option 0 25,500 60,065 02/02/24
Keese Kari Leigh Chief Financial Offi.. Chief Financial Officer Jan 31 Sell 67.74 3,489 236,345 43,323 02/02/24
Keese Kari Leigh Chief Financial Offi.. Chief Financial Officer Jan 31 Option 0 6,167 46,812 02/02/24
COHEN RAYMOND W Chief Executive Offi.. Chief Executive Officer Jan 31 Sell 67.74 35,161 2,381,806 188,835 02/02/24
COHEN RAYMOND W Chief Executive Offi.. Chief Executive Officer Jan 31 Option 0 63,400 223,996 02/02/24
Noblett Karen Chief Medical Office.. Chief Medical Officer Jan 08 Sell 69.0019 15,999 1,103,961 18,216 01/10/24
Noblett Karen Chief Medical Office.. Chief Medical Officer Dec 26 Sell 63.14 8,000 505,120 34,215 12/28/23
Dearen Danny L. President & CFO President & CFO Sep 29 Sell 56.87 7,675 436,477 23,777 10/03/23
Dearen Danny L. President & CFO President & CFO Sep 29 Option 0 11,250 31,452 10/03/23
Dearen Danny L. President & CFO President & CFO Feb 03 Sell 48.62 18,684 908,416 39,235 10/03/23
Dearen Danny L. President & CFO President & CFO Feb 03 Option 0 36,919 57,919 10/03/23
Ford Alfred J Jr Chief Commercial Off.. Chief Commercial Officer Aug 15 Sell 62.3381 14,769 920,671 34,565 08/17/23
Ford Alfred J Jr Chief Commercial Off.. Chief Commercial Officer Jul 28 Sell 62.014 1,500 93,021 49,334 08/01/23
Dearen Danny L. President & CFO President & CFO May 26 Sell 49.79 7,999 398,270 9,202 05/31/23
Dearen Danny L. President & CFO President & CFO Apr 21 Sell 60.22 20,000 1,204,400 17,201 04/25/23
Dearen Danny L. President & CFO President & CFO Apr 21 Option 14.19 13,208 187,422 37,201 04/25/23
Dearen Danny L. President & CFO President & CFO Apr 20 Sell 60.01 2,001 120,080 23,993 04/24/23
Dearen Danny L. President & CFO President & CFO Apr 20 Option 14.19 2,001 28,394 25,994 04/24/23
Dearen Danny L. President & CFO President & CFO Mar 31 Option 13.88 15,000 208,200 38,993 04/04/23
Dearen Danny L. President & CFO President & CFO Mar 31 Sell 55.26 15,000 828,900 23,993 04/04/23
Sama Rinda Chief Operating Offi.. Chief Operating Officer Feb 21 Sell 56.46 23,321 1,316,704 608 02/23/23
Sama Rinda Chief Operating Offi.. Chief Operating Officer Jan 31 Sell 60.94 18,500 1,127,390 75,783 02/02/23
Sama Rinda Chief Operating Offi.. Chief Operating Officer Jan 31 Option 0 30,875 94,283 02/02/23
Ford Alfred J Jr Chief Commercial Off.. Chief Commercial Officer Jan 31 Sell 60.94 9,939 605,683 50,834 02/02/23
Ford Alfred J Jr Chief Commercial Off.. Chief Commercial Officer Jan 31 Option 0 16,500 60,773 02/02/23
Dearen Danny L. President & CFO President & CFO Jan 31 Sell 60.94 13,757 838,352 23,993 02/02/23
Dearen Danny L. President & CFO President & CFO Jan 31 Option 0 25,250 37,750 02/02/23
Woock John EVP, Chief Mktg/Strt.. EVP, Chief Mktg/Strtgy Officer Jan 17 Sell 67.43 30,215 2,037,397 45,976 01/19/23
Woock John EVP, Chief Mktg/Strt.. EVP, Chief Mktg/Strtgy Officer Jan 17 Option 10.69 30,215 322,998 58,020 01/19/23
Lopez Esteban Director Director Dec 13 Sell 67.42 2,000 134,840 3,600 12/15/22
Noblett Karen Chief Medical Office.. Chief Medical Officer Sep 12 Sell 78.16 32,483 2,538,871 31,599 09/20/22
Noblett Karen Chief Medical Office.. Chief Medical Officer Sep 12 Option 20.01 32,483 649,985 64,082 09/20/22
Dearen Danny L. See Remarks See Remarks Sep 13 Sell 75.60 656 49,594 7,500 09/15/22
Woock John Chief Marketing Offi.. Chief Marketing Officer Sep 08 Option 1.53 7,500 11,475 49,676 09/12/22
Woock John Chief Marketing Offi.. Chief Marketing Officer Sep 08 Sell 75 7,500 562,500 45,976 09/12/22
Noblett Karen Chief Medical Office.. Chief Medical Officer Sep 07 Sell 71.5319 10,454 747,794 31,599 09/09/22
Woock John Chief Marketing Offi.. Chief Marketing Officer Aug 25 Sell 73.13 7,500 548,475 45,976 08/26/22
Dearen Danny L. See Remarks See Remarks Aug 11 Option 8.86 37,502 332,268 58,156 08/15/22
Dearen Danny L. See Remarks See Remarks Aug 11 Sell 71.26 50,000 3,563,000 8,156 08/15/22
Woock John Chief Marketing Offi.. Chief Marketing Officer Aug 10 Option 1.63 7,500 12,225 68,476 08/12/22
Woock John Chief Marketing Offi.. Chief Marketing Officer Aug 10 Sell 69.78 15,000 1,046,700 53,476 08/12/22
Sama Rinda Chief Operating Offi.. Chief Operating Officer Aug 10 Option 18.07 33,850 611,670 88,508 08/12/22
Sama Rinda Chief Operating Offi.. Chief Operating Officer Aug 10 Sell 69.73 33,850 2,360,360 54,658 08/12/22
COHEN RAYMOND W Chief Executive Offi.. Chief Executive Officer Aug 08 Sell 70.91 44,000 3,120,040 149,635 08/10/22